Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes

por Yoon, Kun‐Ho, Kang, Jahoon, Kwon, Se Chang, Trautmann, Michael E., Hompesch, Marcus, Stewart, John, Sorli, Christopher H.
Publicado 2020

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

por Hompesch, Marcus, Kang, Jahoon, Han, OakPil, Trautmann, Michael E, Sorli, Christopher H, Ogbaa, Ike, Stewart, John, Morrow, Linda
Publicado 2021

Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study

por Del Prato, Stefano, Kang, Jahoon, Trautmann, Michael E., Stewart, John, Sorli, Christopher H., Derwahl, Michael, Soto, Alfonso, Yoon, Kun‐Ho
Publicado 2020

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

por Pratley, Richard E., Kang, Jahoon, Trautmann, Michael E., Hompesch, Marcus, Han, OakPil, Stewart, John, Sorli, Christopher H., Jacob, Stephan, Yoon, Kun‐Ho
Publicado 2019

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

por Pratley, Richard E, Jacob, Stephan, Baek, Seungjae, Trautmann, Michael E, Hompesch, Marcus, Han, OakPil, Stewart, John, Sorli, Christopher H, Shaunik, Alka, Yoon, Kun-Ho
Publicado 2022